Cigarette smokers have exaggerated alveolar barrier disruption in response to lipopolysaccharide inhalation.
Cigarette smokers have exaggerated alveolar barrier disruption in response to lipopolysaccharide inhalation.
复制标题
DOI:
10.1136/thoraxjnl-2015-207886
复制
发表时间:
2016-12
期刊:
影响因子:
10
通讯作者:
Calfee CS
中科院分区:
文献类型:
--
作者:
Moazed F;Burnham EL;Vandivier RW;O'Kane CM;Shyamsundar M;Hamid U;Abbott J;Thickett DR;Matthay MA;McAuley DF;Calfee CS
Cigarette smoke exposure is associated with an increased risk of the acute respiratory distress syndrome (ARDS); however, the mechanisms underlying this relationship remain largely unknown. To assess pathways of lung injury and inflammation in smokers and nonsmokers with and without lipopolysaccharide (LPS) inhalation using established biomarkers. We measured plasma and bronchoalveolar lavage (BAL) biomarkers of inflammation and lung injury in smokers and non-smokers in 2 distinct cohorts of healthy volunteers, one unstimulated (n=20) and one undergoing 50 µg LPS inhalation (n=30). After LPS inhalation, cigarette smokers had increased alveolar capillary membrane permeability as measured by BAL total protein, compared to nonsmokers (median: 274 vs 208 µg/mL, p = 0.04). Smokers had exaggerated inflammation compared to nonsmokers, with increased BAL interleukin-1β (p = 0.002), neutrophils (p = 0.02), plasma interleukin-8 (p = 0.003), and plasma matrix metalloproteinase-8 (p = 0.006). Alveolar epithelial injury after LPS was more severe in smokers than non-smokers, with increased plasma (p = 0.04) and decreased BAL (p = 0.02) surfactant protein D. Finally, smokers had decreased BAL vascular endothelial growth factor (VEGF) (p < 0.0001) with increased soluble VEGF receptor-1 (p = 0.0001). Cigarette smoke exposure may predispose to ARDS through an abnormal response to a “second hit,” with increased alveolar-capillary membrane permeability, exaggerated inflammation, increased epithelial injury and endothelial dysfunction. LPS inhalation may serve as a useful experimental model for evaluation of the acute pulmonary effects of existing and new tobacco products.